Purpose

The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.

Conditions

Eligibility

Eligible Ages
All ages
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

For urinary tract procedure cohort: 1. Subject intends to undergo diagnostic and/or therapeutic urinary tract procedure with qualified BSC device(s) 2. Subject is willing and able to complete all follow-up visits For BPH cohort: 1. Subject is ≥ 40 years of age 2. Subject with a diagnosis of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms 3. Subject intends to undergo BPH treatment with qualified BSC device(s) 4. Subject is willing and able to complete all follow-up visits

Exclusion Criteria

For urinary tract procedure cohort: 1. Subject requires simultaneous surgical treatment for BPH 2. Unwilling or unable to provide consent 3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.) For BPH cohort: 1. Subject requires simultaneous upper urinary calculi lithotripsy procedure (not applicable to bladder calculi) 2. Unwilling or unable to provide consent 3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.)

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Urinary Tract Procedure Cohort Subjects intend to undergo diagnostic and/or therapeutic urinary tract procedure with study device(s)
  • Device: Ureteroscope system
    LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring
  • Device: Laser system
    Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology
Benign Prostatic Hyperplasia Cohort Subjects are at least 40 years of age diagnosed with BPH with lower urinary tract symptoms and intend to undergo BPH treatment with study device(s)
  • Device: Laser system
    Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology

Recruiting Locations

University of Miami Hospital
Miami 4164138, Florida 4155751 33442
Contact:
Elena Cortez
305-216-0394
ecortizas@med.miami.edu

Indiana University Medical Center
Indianapolis 4259418, Indiana 4921868 46202
Contact:
Stephanie Wofford
sdwillia@iu.edu

More Details

NCT ID
NCT06982235
Status
Recruiting
Sponsor
Boston Scientific Corporation

Study Contact

Winnie Chen
952-930-6000
SALTregistry@bsci.com

Detailed Description

The SALT study is a multi-center, open label, non-randomized, prospective observational study to document on-going post-market safety and device performance data of BSC commercially available study devices that are used in diagnostic and/or therapeutic urinary tract procedures or surgical treatment for BPH. Enrolled subjects undergoing diagnostic or therapeutic procedures using study devices will be followed for 1 year after the index procedure is complete.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.